Brigimadlin

Generic Name: Brigimadlin

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₂₅Cl_₂FN_₄O_₃

CAS Number: 2095116-40-6

Unique Ingredient Identifier: 9A934ZAN94

Clinical Trials

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Phase 2

Recruiting

Conditions: Solid Tumours

Interventions: Drug: Brigimadlin

First Posted Date: 2024-10-01

Last Posted Date: 2025-05-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT06619509

Locations: 🇭🇺
Clinexpert Gyongyos, Gyongyos, Hungary
🇯🇵
Okayama University Hospital, Okayama, Okayama, Japan
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt, Germany

and more 53 locations

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Phase 3

Withdrawn

Conditions: Myxofibrosarcoma (MFS)
Advanced Soft Tissue Sarcoma
Undifferentiated Pleomorphic Sarcoma (UPS)

Interventions: Drug: Ezabenlimab
Drug: Brigimadlin
Drug: Gemcitabine
Drug: Docetaxel

First Posted Date: 2024-04-17

Last Posted Date: 2024-07-17

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT06370871

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 3

Active, not recruiting

Conditions: Liposarcoma, Dedifferentiated

Interventions: Drug: Brigimadlin

First Posted Date: 2023-09-28

Last Posted Date: 2025-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 138

Registration Number: NCT06058793

Locations: 🇬🇧
The Christie, Manchester, United Kingdom
🇦🇷
Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma de Bs As, Argentina
🇧🇷
Pronutrir, Fortaleza, Brazil

and more 53 locations

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)
Drug: [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)
Drug: BI 907828

First Posted Date: 2022-11-14

Last Posted Date: 2025-01-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT05613036

Locations: 🇭🇺
PRA Hungary Ltd., Budapest, Hungary

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Phase 2

Active, not recruiting

Conditions: Pancreatic Neoplasms
Lung Neoplasms
Solid Tumors
Biliary Tract Cancer
Bladder Cancer

Interventions: Drug: brigimadlin

First Posted Date: 2022-08-23

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 99

Registration Number: NCT05512377

Locations: 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 57 locations

A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: BI 907828
Drug: Rifampicin
Drug: Itraconazole

First Posted Date: 2022-05-12

Last Posted Date: 2025-05-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33

Registration Number: NCT05372367

Locations: 🇪🇸
Hospital Quiron. I.C.U., Barcelona, Spain
🇪🇸
Fundación Jiménez Díaz, Madrid, Spain
🇪🇸
CIO Clara Campal, Madrid, Spain

and more 4 locations

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2

Active, not recruiting

Conditions: Liposarcoma, Dedifferentiated

Interventions: Drug: Brigimadlin (BI 907828)
Drug: Doxorubicin

First Posted Date: 2022-02-01

Last Posted Date: 2025-03-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 401

Registration Number: NCT05218499

Locations: 🇮🇹
A.O. Univ. Policlinico Giaccone, Palermo, Italy
🇩🇪
Helios Klinikum Berlin-Buch, Berlin, Germany
🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

and more 105 locations

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: BI 907828
Drug: ezabenlimab
Drug: BI 754111

First Posted Date: 2019-05-28

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 120

Registration Number: NCT03964233

Locations: 🇫🇷
INS Bergonie, Bordeaux, France
🇫🇷
CTR Leon Berard, Lyon, France
🇫🇷
INS Gustave Roussy, Villejuif, France

and more 20 locations

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: BI 907828

First Posted Date: 2018-02-28

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 267

Registration Number: NCT03449381

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States

and more 24 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy